论文部分内容阅读
[目的]研究调强放疗联合同步化疗对于进展期胃癌的临床效果。[方法]选取我院收治的145例进展期胃癌患者为研究对象,将其随机分成观察组和对照组,给予对照组患者同步化疗治疗,观察组患者在对照组的基础上给予调强放疗治疗,观察2组患者的疗效、生存率、复发率、转移率、不良反应发生率等。[结果]观察组患者的有效率为64.0%,对照组为45.7%,组间比较差异有统计学意义(P<0.05)。在不良反应上,观察组为9.3%,对照组为11.4%,差异无统计学意义。在随访结果上,观察组患者的生存率、局部复发率、远处转移率均明显低于对照组,组间比较差异有统计学意义(P<0.05)。[结论]调强放疗联合同步化疗治疗进展期胃癌患者疗效确切,有助于降低病死率,提高患者的生存质量,且不良反应少,安全性高,值得临床推广应用。
[Objective] To study the clinical effect of intensity modulated radiotherapy combined with concurrent chemotherapy on advanced gastric cancer. [Methods] A total of 145 patients with advanced gastric cancer admitted to our hospital were enrolled in this study. They were randomly divided into observation group and control group. Patients in control group were treated with synchronous chemotherapy. Patients in observation group were given IMRT on the basis of control group The curative effect, survival rate, recurrence rate, metastasis rate and incidence of adverse reactions in the two groups were observed. [Results] The effective rate of observation group was 64.0% and that of control group was 45.7%. The difference between the two groups was statistically significant (P <0.05). Adverse reactions, the observation group was 9.3%, control group was 11.4%, the difference was not statistically significant. In the follow-up results, the survival rate, local recurrence rate and distant metastasis rate in the observation group were significantly lower than those in the control group, the difference was statistically significant (P <0.05). [Conclusion] IMRT combined with concurrent chemotherapy is effective in treating patients with advanced gastric cancer, which will help to reduce the mortality and improve the quality of life of patients with less adverse reactions and high safety. It is worthy of clinical application.